Navigation Links
Added Drug Aids MS Treatment
Date:2/16/2010

Multi-center study shows daclizumab reduces disease activity when added to interferon beta

TUESDAY, Feb. 16 (HealthDay News) -- Adding the drug daclizumab to standard treatment with interferon beta may reduce multiple sclerosis disease activity more than interferon beta alone, a new study reports.

Previous non-randomized studies found that daclizumab -- a humanized monoclonal antibody -- reduced MS disease activity.

This new phase 2 study at 51 centers in the United States, Canada, Germany, Italy and Spain included 230 patients with active relapsing MS who were taking interferon beta. They were randomly selected to also receive either high-dose daclizumab (2 milligrams/kilogram every two weeks), low-dose daclizumab (1 milligram/kilogram every four weeks) or an inactive placebo. The combined treatments continued for 24 weeks.

MRI scans of the patients' brains were taken every four weeks between weeks 8 and 24 of the study in order to determine the number of new or enlarged gadolinium contrast-enhancing lesions, which indicate MS disease activity.

By the end of the study, the adjusted mean number of new or enlarged gadolinium contrast-enhancing lesions was 1.32 in the high-dose group (75 patients), 3.58 in the low-dose group (78 patients) and 4.75 in the placebo group (77 patients).

Levels of CD56bright natural killer cells were seven to eight times higher in patients taking daclizumab than in those taking the placebo.

"This study provides confirmatory data that daclizumab treatment causes an expansion of CD56bright natural killer cells and adds support to the theory that expansion of CD56bright natural killer cells might mediate some of the effects of daclizumab on reducing multiple sclerosis lesion activity. In addition to the results of previous trials of daclizumab in multiple sclerosis, several lines of evidence have suggested a potential immunoregulatory function for CD56bright natural killer cells: they are expanded during conditions of natural immune tolerance, for example, pregnancy," the researchers from the Neurovirology Research Laboratory at the VA Medical Center in Salt Lake City, and the University of Utah, reported in a news release.

"This randomized controlled trial indicates that daclizumab can reduce new lesion formation in relapsing multiple sclerosis compared with interferon-beta alone," the researchers concluded. "Multiple sclerosis treatments that have the potential to improve in risk-benefit ratios when compared with available treatments are needed; thus, additional studies to define the long-term clinical risks and benefits of daclizumab are warranted."

The study was released online Feb. 15 in advance of publication in the April issue of The Lancet Neurology.

More information

The U.S. National Institute of Neurological Disorders and Stroke has more about multiple sclerosis.



-- Robert Preidt



SOURCE: The Lancet Neurology, news release, Feb. 15, 2010


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Corals added to IUCN Red List of Threatened Species for first time
2. Halozyme Therapeutics Added to Nasdaq Biotech Index
3. Thalidomide Added to Standard Therapy Prolongs Overall Survival in Newly Diagnosed Multiple Myeloma Patients Over Age 75
4. An Event Added to Celebrate and Empower North Carolina Women
5. Blood pressure drug may have added benefit
6. VA Has Added 20 New Vet Centers
7. Turner Investment Partners Added to AHA Diversified Equity Fund
8. Kelsey Grammer, Ben Stiller, Maroon 5 and The Roots Added to COMEDY CENTRALs(R) Live On-air Charity Special Night of Too Many Stars: An Overbooked Concert for Autism Education Hosted by Jon Stewart on Sunday April 13, at 8 p.m. ET
9. IPC The Hospitalist Company Added to Russell 2000 Index
10. Welchol(TM) Added to the American College of Endocrinology/American Association of Clinical Endocrinologists Road Maps to Achieve Glycemic Control in Patients with Type 2 Diabetes Mellitus
11. Avastin Added to Chemo Helps Women With Advanced Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2017)... Kansas City, MO (PRWEB) , ... July 24, 2017 , ... ... for the acclaimed Saint Luke’s Marion Bloch Neuroscience Institute (SLMBNI), part of ... an interim basis since 2016. , Cheerag D. Upadhyaya, MD. M.Sc., FAANS joins ...
(Date:7/24/2017)... , ... July 24, 2017 , ... ... federal Substance Abuse and Mental Health Services Administration’s (SAMHSA) State Targeted Response to ... Department of Health Care Services, will facilitate the development of a hub and ...
(Date:7/24/2017)... ... 24, 2017 , ... Peruvian Ayahuasca retreat, East West Lodge, ... to and divided between two full-time university students enrolled in U.S. or Canadian ... To apply for the scholarship, students are asked to submit an essay between ...
(Date:7/24/2017)... ... ... Axiad IDS , a leading provider of trusted identities for enterprise, ... to expand its solution to help government contractors more quickly and cost-effectively comply with ... address the authentication requirements within NIST SP800-171, but no matter how you address ...
(Date:7/24/2017)... ... ... that, although people are taking more steps to protect themselves from sunburn, half of all ... sunburn within the past year. It’s common and people have been dealing with them since ... people become conscientious of the risks that accompany sunburns. , The team at AloeVera.com ...
Breaking Medicine News(10 mins):
(Date:7/12/2017)... is a revolutionary new product that relieves painful carpal tunnel syndrome ... affects more than 8 million people a year. Women suffer from ... methods of treating CTS are painful surgery, the use of NSAIDs ... ... a clear patch worn on the palm of the hand. It ...
(Date:7/11/2017)... 11, 2017  Sysmex America, Inc., a leading ... equipment as well as middleware information systems technology, ... make quality assurance easier and more risk free ... known for the innovation that it delivers to ... quality assurance processes to a new level with ...
(Date:7/10/2017)... July 10, 2017  BDI Group subsidiary Pathway ... support services organization serving specialty pharmacies, home infusion ... of four significant, value-added member programs designed to ... manage reimbursement and improve access and affordability for ... Pathway ...
Breaking Medicine Technology: